TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.

Matthew I Milowsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.